Analysts think SRPT stock price could increase by 247%
Apr 05, 2025, 11:25 AM
16.74%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
25 analysts think SRPT stock price will increase by 246.81%. The current median analyst target is $188.70 compared to a current stock price of $54.41. The lowest analysts target is $75.75 and the highest analyst target is $225.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
